Reimbursement has been cited as a key barrier to the adoption of precision medicine into clinical care.1 This issue has recently attracted attention with the March 2018 Centers for Medicare & Medicaid Services (CMS) national coverage determination on next-generation sequencing tests for patients with advanced cancer.2
Phillips KA. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA. 2018;319(23):2379–2380. doi:10.1001/jama.2018.4863
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.